InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or ...
With optimal treatment, myeloma isn't immediately life-threatening. Many patients live for years after their diagnosis, often ...
C4 Therapeutics has begun dosing in a Phase Ib study assessing cemsidomide and elranatamab (Elrexfio) in patients with ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...
Shares of C4 Therapeutics rose after the company dosed its first patient in a Phase 1b trial for a multiple myeloma treatment. Shares were up 6.6% to $2.67 in Wednesday afternoon trading. The stock is ...
The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...
Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment. At the Miami Cancer Institute’s ...
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 ...
Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as ...
Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger individuals, we are seeing an impact in older individuals as well that is ...
The FDA approved a steroid-sparing Tecvayli and Darzalex Faspro combo for relapsed myeloma, offering an 83% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results